Remove Bioinformatics Remove Pharmaceutical Companies Remove Pharmacokinetics
article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part II)

Practical Cheminformatics

While large pharmaceutical companies have data on thousands or even millions of compounds, this data is rarely shared due to intellectual property concerns. In addition to optimizing potency against a target of interest, we must design selective compounds with optimal pharmacokinetic profiles and a host of other desirable properties.

Drugs 139
article thumbnail

Accelerating Drug Discovery Through Repurposing

DrugBank

This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs.

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

In October 2020 , we completed a second clinical study in healthy volunteers to compare the pharmacokinetics of Treprostinil Technosphere to Tyvaso. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. NON-GAAP FINANCIAL INFORMATION.

FDA 40